You just read:

Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes

News provided by

Lexicon Pharmaceuticals, Inc.

25 Oct, 2016, 06:58 ET